Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Icariin Induces Synoviolin Expression through NFE2L1 to Protect Neurons from ER Stress-Induced Apoptosis

  • Fei Li ,

    lifei_2009@163.com (FL); fangd@northwestern.edu (DF)

    Affiliations Department of Pharmacology and the Key Laboratory of Basic Pharmacology of Guizhou Province, Zunyi Medical College, Zunyi, China, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, 303 E. Chicago Ave, Chicago, IL, 60611, United States of America

  • Beixue Gao,

    Affiliation Department of Pathology, Northwestern University Feinberg School of Medicine, 303 E. Chicago Ave, Chicago, IL, 60611, United States of America

  • Hongxin Dong,

    Affiliation Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, 303 E. Chicago Ave, Chicago, IL, 60611, United States of America

  • Jingshan Shi,

    Affiliation Department of Pharmacology and the Key Laboratory of Basic Pharmacology of Guizhou Province, Zunyi Medical College, Zunyi, China

  • Deyu Fang

    Affiliation Department of Pathology, Northwestern University Feinberg School of Medicine, 303 E. Chicago Ave, Chicago, IL, 60611, United States of America

Abstract

By suppressing neuronal apoptosis, Icariin is a potential therapeutic drug for neuronal degenerative diseases. The molecular mechanisms of Icariin anti-apoptotic functions are still largely unclear. In this report, we found that Icariin induces the expression of Synoviolin, an endoplasmic reticulum (ER)-anchoring E3 ubiquitin ligase that functions as a suppressor of ER stress-induced apoptosis. The nuclear factor erythroid 2-related factor 1 (NFE2L1) is responsible for Icariin-mediated Synoviolin gene expression. Mutation of the NFE2L1-binding sites in a distal region of the Synoviolin promoter abolished Icariin-induced Synoviolin promoter activity, and knockdown of NFE2L1 expression prevented Icariin-stimulated Synoviolin expression. More importantly, Icariin protected ER stress-induced apoptosis of PC12 cells in a Synoviolin-dependent manner. Therefore, our study reveals Icariin-induced Synoviolin expression through NFE2L1 as a previously unappreciated molecular mechanism underlying the neuronal protective function of Icariin.

Introduction

Icariin, the prenyl acetylation of kaempferide 3,7-O-diglucoside, is a flavonoid derived from the genus Epimedium, a plant known as Horny Goat Weed or Yin Yang Huo [1]. Extracts from these plants are used in Chinese herbal medicine to enhance erectile function. Recent studies, including work from our laboratory, have shown that Icariin has a potent neuronal protective activity and prevents neuronal degenerative disease in mouse models [220]. Several pathways are likely involved in Icariin-induced neuronal cell proliferation and inhibition of apoptosis [13, 14, 2127]. We have shown that Icariin inhibits β-amyloid peptide segment 25–35—induced expression of β-secretase in the rat hippocampus [10, 2830]. Icariin also attenuates β-amyloid–induced neurotoxicity by inhibition of tau protein hyperphosphorylation [9]. More recently, Zhang et al observed that Icariin may prevent corticosterone-induced cell death via activation of the PI3-K/Akt pathway in neuronal cells [4]. In addition to its direct effect on neurons, Icariin inhibits both TAK1/IKK/NF-kappaB and JNK/p38 MAPK pathways in microglial cells to suppress inflammatory cytokine production, thus indirectly protecting neurons from inflammatory injury [7, 13, 16, 3134]. An elevated ER stress response has been detected in brain tissues from patients with neuronal degenerative diseases, and ER stress-induced cell death has been considered as one of the possible casual factors of neuronal cell death in these diseases [3542]. However, whether the neural protective activity of Icariin involves suppression of ER stress-induced neuronal cell apoptosis remains to be determined.

Synoviolin, also known as Hrd1, is an ER membrane-spanning protein. Synoviolin was initially identified as a ubiquitin ligase involved in degrading misfolded proteins [43, 44]. Since Hrd1 expression is often upregulated in synovial fibroblasts in patients with rheumatoid arthritis, it was renamed Synoviolin [45]. We recently reported that proinflammatory cytokines, including TNF-α and IL-1β, are responsible for inducing Synoviolin expression in synovial fibroblasts [46]. Synoviolin achieves its anti-apoptotic functions through multiple mechanisms: first, Synoviolin degrades misfolded proteins to suppress ER stress-induced cell death [47]; second, we discovered that Synoviolin ubiquitinates IRE1α (inositol-requiring enzyme 1α), a critical kinase regulating ER stress-induced cell death [48]; and third, Synoviolin has been identified as an E3 ubiquitin ligase that targets p53, implying that Synoviolin may inhibit apoptosis through cytoplasmic p53 degradation [49].

In the current study, we observed that Icariin induces expression of the anti-apoptotic factor Synoviolin at the gene transcriptional level. Further analysis demonstrated that the transcription factor NFE2L1 is responsible for Icariin-induced Synoviolin mRNA transcription. Consequently, Icariin protects ER stress-induced neuronal cell death in a Synoviolin-dependent manner. Thus, our studies identify Synoviolin as a molecular link between Icariin and its neuronal anti-apoptotic activity.

Materials and Methods

Cells and reagents

PC12 cells were cultured in D-MEM (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 50 μM β-mercaptoethanol, 100 mM sodium pyruvate, 100 mM HEPES buffer, and 1% penicillin/streptomycin. Specific antibodies against Synoviolin (H7790) and β-Actin were purchased from Sigma (St. Louis, MO, USA) and NFE2L1 (SC-721) from Santa Cruz (Santa Cruz, CA, USA). siRNA specific to Synoviolin and NFE2L1 (SR504532), as well as controls, were from Origene (Rockville, MD, USA).

Immunoblot analysis

PC12 cells were treated with Icariin at the indicated concentrations and harvested after 24 hours. Cells were lysed in radioimmunoprecipitation (RIPA) buffer containing phosphatase inhibitors and protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA). Cell lysates were boiled with Laemlli’s buffer, then subjected to SDS-PAGE and transferred to nitrocellulose membrane. Membranes were blocked with 5% milk in TBS-T, incubated with the indicated primary antibodies overnight, followed by incubation with HRP-conjugated secondary antibody as described [50]. Immunoblots were developed using enhanced chemiluminescent substrate (Pierce, Rockford, IL, USA) and visualized using the ChemiDoc XRS+ System (BioRad, Hercules, CA, USA).

Real-time quantitative PCR

Quantification of mRNA expression was performed as described [51]. 106 PC12 cells were lysed in Trizol (Invitrogen, Carlsbad, CA, USA), and RNA isolated per manufacturer’s instructions. 1 μg of isolated RNA was then reversed transcribed using the qScript cDNA synthesis kit (Quanta BioSciences, Gaithersburg, MD, USA). Real-time quantitative PCR (qPCR) was performed in duplicate wells using the iCycler Sequence and SsoFast SYBR Green Supermix (BioRad). Relative expression was normalized to expression of Actb.

Luciferase reporter assay

The Synoviolin promoter region was amplified by PCR and subcloned into the pGL4.10(luc2) vector (Promega, Madison, WI, USA). PC12 cells in 12-well plates were transfected with pRL-TK (Promega) and various pSynoviolin luciferase plasmids as indicated using Lipofectamine transfection reagent (Invitrogen Life Technologies, San Diego, CA, USA). Luciferase assays were performed as previously reported [52]. The pRL-TK plasmid contains the Renilla reniformis (sea pansy) luciferase gene under the transcriptional control of the herpesvirus thymidine kinase promoter and constitutively expresses low levels of renilla luciferase. Transfected cells were lysed, and the luciferase activities in the cell lysates were analyzed using the Dual Luciferase Reporter assay kit (Promega). Luciferase activity was measured as relative light units (RLUs) using a luminometer (Turner BioSystems, Inc. Sunnyvale, CA, USA).

Chromatin immunoprecipitation (ChIP) assay

PC12 cells were treated with or without Icariin for 24 hours and used for ChIP analysis as reported [53]. Cells were cross-linked with 1% formaldehyde, and lysed with SDS lysis buffer. Cell lysates were sonicated, and 5% of cell lysate was removed and used to determine the total amount of target DNA in input. Remaining cell lysates were diluted in ChIP dilution buffer. Immunoprecipitation was performed with either NEF2L1 or Xbp-1 antibodies (4 μg) at 4°C overnight. Immune complexes were then mixed with salmon sperm DNA/protein agarose 50% slurry at 4°C for 1 h. After immunoprecipitates were washed sequentially with low salt buffer, high salt buffer, LiCl wash buffer, and Tris EDTA, DNA-protein complexes were eluted with elution buffer, and cross-linking was reversed. Genomic DNA was extracted using phenol/chloroform, and ethanol-precipitated DNA was re-suspended in Tris EDTA and used for the real-time PCR analysis.

ER stress-induced cell death

PC12 cells were treated with 10 μM tunicamycin (EMD, San Diego, CA, USA) for 24 hours with or without addition of Icariin. Treated cells were collected and stained with FITC-conjugated Annexin V as described [54]. Cell apoptosis was analyzed by flow cytometry to detect expression of Annexin V (eBioscience, San Diego, CA, USA).

Results

Icariin induces Synoviolin expression in neuroblastic cells

We previously discovered that Icariin suppresses neuronal cell death and protects mice against neuronal degenerative disease [10]. To investigate the underlying molecular mechanisms, we analyzed the effects of Icariin on the protein expression of Synoviolin, an anti-apoptotic E3 ubiquitin ligase. PC12 cells were cultured in the presence of Icariin for 24 hours, the treated cells were collected and lysed, and protein expression levels of Synoviolin were examined by immunoblotting. As shown in Fig. 1A, Synoviolin protein expression dramatically increased in PC12 cells after treatment with 5 μM Icariin, indicating that Icariin induces Synoviolin expression in neuronal PC12 cells. We further demonstrated that Icariin treatment enhanced Synoviolin expression in a dose-dependent manner (Fig. 1B)

thumbnail
Fig 1. Icariin induces Synoviolin expression at the transcriptional level.

PC12 cells were cultured with or without Icariin at different concentrations as indicated. (A & B) 24 hours after Icariin treatment, protein expression levels of Synoviolin (top panels) were determined by immunoblotting using β-Actin as a loading control (bottom panels). (C) Total RNA was isolated from PC12 cells 24 hours after treatment with or without Icariin. The levels of Synoviolin mRNA were determined by real-time qPCR using GAPDH as an internal control.

https://doi.org/10.1371/journal.pone.0119955.g001

Next we asked whether Icariin induces Synoviolin expression at the transcriptional level. Total RNA was extracted from Icariin-treated and untreated control PC12 cells. mRNA levels of Synoviolin were determined by real-time qPCR using β-actin mRNA as an internal control. As expected, Synoviolin mRNA levels were significantly higher in the Icariin-treated cells compared to controls (Fig. 1C). Similar to our immunoblot analysis, Icariin induced Synoviolin mRNA expression in a dose-dependent manner. These results indicate that Icariin induces Synoviolin expression at the mRNA level.

Icariin enhances Synoviolin reporter activity in PC12 cells

To elucidate the molecular mechanisms underlying Icariin-induced Synoviolin mRNA expression, we subcloned the promoter region of Synoviolin into a luciferase vector (Fig. 2A). We then used the Synoviolin reporter plasmid to test whether Icariin induces Synoviolin expression at the transcriptional level. High levels of luciferase activity were detected in PC12 cells when transfected with Synoviolin reporter plasmids carrying either 2kb or 4kb of the Synoviolin promoter, indicating that this region carries the regulatory elements required for Synoviolin gene transcription. We also detected a significantly higher luciferase activity when the 4kb Synoviolin promoter region reporter was transfected into PC12 cells compared to the 2kb promoter region reporter, suggesting that the distal 2kb region is important for Synoviolin gene transcription. When the transfected cells were treated with Icariin, a significant increase in luciferase activity was detected in cells transfected with the Synoviolin 4kb, but not 2kb, reporter, suggesting that the distal 2kb promoter region also carries the element that is positively regulated by Icariin.

thumbnail
Fig 2. The effects of Icariin on Synoviolin reporter activity.

The Synoviolin promoter region was amplified by PCR using genomic DNA from PC12 cells as template. The amplified DNA fragment was subcloned into a luciferase reporter vector. (A) Luciferase reporter plasmids carrying the Synoviolin promoter region (2kb and 4kb) or empty vector control plasmid were transfected into PC12 cells. Two days after transfection, luciferase activity was determined. (B) 24 hours after transfection, cells were treated with or without Icariin for an additional 24 hours and luciferase activity was determined.

https://doi.org/10.1371/journal.pone.0119955.g002

NFE2L1 binding sites are involved in Icariin-mediated Synoviolin expression

Analysis of the transcription factor binding sites in the 4kb Synoviolin promoter identified one Xbp-1 binding site within the proximal 2kb region and five NFE2L1 binding sites in the distal 3.5–4kb region (Fig. 3A & B). We speculated that the NFE2L1 binding sites are involved in Icariin-mediated Synoviolin gene transcription. To test this hypothesis, the distal promoter region containing the five NFE2L1 binding sites was deleted and luciferase reporter activity was determined (Fig. 3B). As shown in Fig. 3C, deletion of the NFE2L1-binding site region significantly reduced Synoviolin reporter activity, indicating that NFE2L1 is a transcription factor that acts on the Synoviolin promoter in PC12 cells. Interestingly, deletion of the NFE2L1-binding sites in the Synoviolin promoter completely abolished Icariin-stimulated Synoviolin reporter activity (Fig. 3D). To confirm these observation, we generated point mutations of each binding sites (Fig. 3B). As shown in Fig. 3E, mutation of all five NFE2L1-binding sites dramatically inhibited Synoviolin transcription activity. Notably, consistent to our results using the deletion mutate, icariin failed to induce Synoviolin transcription when all the five NFE2L1-binding sites were mutated. In contrast, mutation of the Xbp-1 binding sites, while inhibited the basal level of Synoviolin transcription activity, did not affect icariin-induced Synoviolin expression (Fig. 3E). These results suggest NFE2L1 is responsible for Icariin-induced Synoviolin expression.

thumbnail
Fig 3. Icariin stimulates Synoviolin reporter activity through NFE2L1 binding sites.

(A) The distal region that carries the five NFE2L1 transcription factor-binding sites (red) are shown. (B) The 4-Kb Synoviolin promoter were cloned into a luciferase reporter plasmid. The NFE2L1- (red lines) and Xbp-1- binding site (yellow line) are indicated. The deletion (second) or point mutation of all the five NFE2L1 (3rd panel) or the Xbp-1 (bottom panel) are illustrated. (C) Luciferase reporter plasmids containing the 4kb Synoviolin promoter or a mutant with the four NFE2L1 binding sites deleted (Syvn/ΔNFE2L1) were transfected into PC12 cells. 48 hours after transfection, luciferase activity in the lysates of transfected cells was determined. (D & E) The Synoviolin luciferase reporter plasmids or each of the mutants in (B) were transfected into PC12 cells. One day after transfection, cells were treated with Icariin for an additional 24 hours. Cells were then collected and lysed and luciferase activity was determined. Error bars represent data from 5 independent experiments (Mean ± SD). Student’s t test was used for the statistical analysis. NS: not significant, *p<0.05 and **p<0.01.

https://doi.org/10.1371/journal.pone.0119955.g003

Icariin induces Synoviolin gene transcription in an NFE2L1-dependent manner

We then used an shRNA-mediated knockdown approach to test our hypothesis that Icariin promotes Synoviolin gene expression through NFE2L1. Immunoblotting analysis confirmed that a specific shRNA efficiently suppressed NFE2L1 protein expression in PC12 cells (Fig. 4A). ChIP analysis detected a direct binding of the NFE2L1 to the distal region of Synoviolin promoter, which was largely diminished by NFE2L1 knockdown. Notably, Icariin treatment significantly increased NFE2L1 binding to Synoviolin promoter in PC12 cells (Fig. 4B). In contrast, Xbp-1 binding to Synoviolin promoter was not affected by Icariin treatment (Fig. 4C). In addition, we detected an approximate 60% reduction in Synoviolin mRNA levels in PC12 cells with NFE2L1 knockdown compared to control shRNA transfected cells. Interestingly, in contrast to the average 3-fold increase in Synoviolin mRNA expression seen upon Icariin treatment of control shRNA transfected PC12 cells, Icariin failed to enhance Synoviolin mRNA transcription in PC12 cells when NFE2L1 was knocked down. These results clearly indicate that Icariin enhances Synoviolin expression in an NFE2L1-dependent manner.

thumbnail
Fig 4. NFE2L1 knockdown abolishes Icariin-induced Synoviolin expression.

(A) PC12 cells were transfected with NFE2L1 shRNA or control shRNA. Two days after transfection, the expression levels of NFE2L1 were analyzed by immunoblotting using anti-NFE2L1 Abs (top panel). The expression levels of tubulin protein were determined as a loading control (bottom panel). (B & C) PC12 or its NFE2L1 knockdown cells were treated with or without Icariin for 24 hours. ChIP assay using anti-NFE2L1 (B) or with anti-Xbp-1 (C) antibodies. Tunicamycin (TM) treated cells were used as a positive control for Xbp-1 ChIP analysis. (D) The Synoviolin luciferase reporter plasmids were co-transfected with NFE2L1-shRNA or control shRNA plasmid into PC12 cells. One day after transfection, cells were treated with or without Icariin for an additional 24 hours. The luciferase activity in the lysates of transfected cells was determined. Error bars represent data from 5 independent experiments (Mean ± SD). Student’s t test was used for the statistical analysis. **p<0.01, and ***p<0.001.

https://doi.org/10.1371/journal.pone.0119955.g004

Icariin protects against neuronal cell death through upregulation of Synoviolin

We and others have shown that Icariin holds great therapeutic potential, with evidence of protection against neuronal degenerative disease in mice. One of the proposed underlying mechanisms is that Icariin protects neuronal cells from apoptosis [9, 10]. Since Synoviolin is an anti-apoptotic factor, our discovery that Icariin induces Synoviolin gene transcription suggested that Icariin may inhibit neuronal cell death through upregulation of Synoviolin. To test this hypothesis, we used an shRNA-mediated gene knockdown approach to inhibit Synoviolin expression and test whether Icariin is able to protect PC12 cells from ER stress-induced apoptosis in the absence of Synoviolin. Synoviolin-specific shRNA largely inhibited Synoviolin expression in PC12 cells as determined by immunoblotting (Fig. 5A). As previously reported, treatment of PC12 cells with the pharmacological ER stress inducer tunicamycin at 10 μg/ml resulted in an average of 30% annexin V-positive apoptotic cells. Importantly, treatment of PC12 cells with Icariin fully protected against tunicamycin-induced cell death (Fig. 5B). As expected, tunicamycin treatment of PC12 cells with Synoviolin knocked down led to an elevated percentage of apoptotic cells, from 30% to approximately 50%. Notably, addition of Icariin failed to protect Synoviolin knockdown PC12 cells from tunicamycin-induced apoptosis (Fig. 5B & 5C), indicating that Synoviolin function is essential for Icariin-mediated protection of neuronal cells from ER stress-induced apoptosis. Real-time PCR analysis confirmed that Synoviolin expression was sufficiently inhibited by siRNA even after Icariin treatment (Fig. 5D). Therefore, our study found that Synoviolin upregulation plays a critical role in the protective function of Icariin.

thumbnail
Fig 5. Icariin protects ER stress-induced PC12 cell death through Synoviolin.

(A) PC12 cells were transfected with Synoviolin shRNA or control shRNA. Two days after transfection, the expression levels of Synoviolin were analyzed by immunoblotting using anti-Synoviolin Abs (top panel). The expression levels of tubulin protein were determined as a loading control (bottom panel). (B & C) ER stress-induced cell death by tunicamycin treatment in wild type control and Synoviolin knockdown cells were analyzed by flow cytometry for the expression of annexin V. Representative images from 5 independent experiments are shown (B). Viability of PC12 cells from 5 independent experiments is shown (Mean ± SD). Student’s t test was used for the statistical analysis. **p< 0.05. NS: not significant. (D) The mRNA expression levels of Synoviolin in WT and Synoviolin knockdown PC12 cells after Icariin treatment was confirmed by real-time PCR. (E) A proposed model of Icariin in protecting PC12 cells against apoptosis. Error bars represent data from 5 independent experiments (Mean ± SD). Student’s t test was used for the statistical analysis. **p<0.01, and ***p<0.001.

https://doi.org/10.1371/journal.pone.0119955.g005

Based on our discoveries, we proposed a model for Icariin in protecting against neuronal cell death (Fig. 5E): Icariin induces Synoviolin expression in PC12 cells through the transcription factor NFE2L1. Upregulated Synoviolin then inhibits PC12 cell apoptosis when the ER stress response occurs.

Discussion

The therapeutic potential of Icariin for the treatment of neuronal degenerative disease has stimulated extensive research into the molecular mechanisms underlying the protective effect of Icariin against apoptosis of neuronal cells. Here, we demonstrated that Icariin protects ER stress-induced PC12 cell death through induction of Synoviolin expression. This conclusion is supported by the following observations: first, Icariin induced both protein and mRNA expression of Synoviolin in PC12 cells; second, the transcription factor NFE2L1 was required for Icariin-mediated Synoviolin promoter activity, with knockdown of NFE2L1 expression largely abolishing Icariin-induced Synoviolin expression; and third, suppression of Synoviolin expression by shRNA-mediated knockdown abolished the ability of Icariin to protect PC12 cells from ER stress-induced cell death.

Synoviolin is a known anti-apoptotic factor during ER stress-induced cell death. A significant reduction in Synoviolin protein levels has been detected in the cerebral cortex of Alzheimer’s disease patients [55]. However, the mediators of Synoviolin transcriptional regulation in neurons remain unclear. Our observations here indicate that the transcription factor NFE2L1 is involved in regulating Synoviolin mRNA transcription in PC12 cells, providing a possible explanation for the reduced Synoviolin expression in the brains of AD patients. Notably, Lee et al discovered that mice with a late-stage deletion of NFE2L1 in neuronal cells have dysregulated proteasome gene expression and develop neurodegeneration syndromes [56]. It will be interesting to study the Synoviolin promoter-binding activity of NFE2L1 in neurons from AD patients. Several studies have shown that Synoviolin suppresses neuronal cell death in human neuronal cells and experimental rodent models of neuronal degenerative disease [47, 55, 5769]. Therefore, our discovery that Icariin induces Synoviolin expression to suppress ER stress-induced neuron cell apoptosis provides a rationale for the clinical application of Icariin in treatment of patients with neuronal degenerative diseases, particularly in patients with reduced Synoviolin expression levels.

There are at least five conserved NFE2L1-specific binding sites on the distal region of the mouse, rat, and human Synoviolin promoter. These NFE2L1-binding sites are absolutely required for Icariin activity in promoting Synoviolin mRNA transcription, as deletion of the five NFE2L1-binding sites fully abolished Icariin-induced Synoviolin reporter activity. NFE2L1 has been identified as a substrate of Synoviolin-mediated ubiquitination and degradation [70, 71]. Therefore, our finding that NFE2L1 is a transcription factor acting on the Synoviolin promoter implies that a negative feedback loop regulates Synoviolin expression. Similarly, the X box protein 1 (Xbp-1) is another transcription factor involved in Synoviolin gene expression [21, 72], and we identified an Xbp-1 binding site in the promoter region of Synoviolin locus. We have previously shown that IRE1α, an ER stress transducer and the only known factor upstream of the Xbp-1 activator that acts by splicing Xbp-1 mRNA, is ubiquitinated and degraded by Synoviolin [48]. A similar negative regulatory feedback loop between Synoviolin and Xbp-1 may also exist. Further studies are needed to explore how these two feedback loops are regulated and whether they occur in different physiological and pathological settings in neurons. In addition to NFE2L1 and Xbp-1, Ets-1 binding sites (EBS-1) have been identified and the Ets-1-mediated Synoviolin expression plays important roles in cellular hemostasis [73]. Moreover, Izumi et al demonstrated that the interleukin enhancer binding factor 3 (ILF-3) activates the Synoviolin promoter via association with GABP-α in rheumatoid synovial cells during joint inflammation [74]. Therefore, Synoviolin gene appears to be regulated by multiple transcription factors.

Our study shows that a full protection against ER stress-induced PC12 cell death requires Synoviolin expression. It has been well established that Synoviolin is a critical anti-apoptotic factor that suppresses ER stress-induced cell death by directly degrading misfolded proteins through the ubiquitin pathway [75]. Therefore, together with the fact that the ER stress response is often associated with the pathogenesis of neuronal degenerative diseases in humans [3542], our study suggests that Icariin may be particularly effective in the treatment of neuronal degenerative diseases with elevated ER stress response.

Supporting Information

S1 Fig. Values of the graph figures in the study.

The averages values and their standard deviations (mean ± SD) are indicated for the figures including Fig. 1C, 2B & C, 3C-E, 4B-D and 5C & D.

https://doi.org/10.1371/journal.pone.0119955.s001

(PDF)

Author Contributions

Conceived and designed the experiments: FL DF. Performed the experiments: FL BG. Analyzed the data: FL DF. Wrote the paper: HD JS DF.

References

  1. 1. Liang HR, Yan WM, Li JS, Yang CS. [Chemical studies of Epimedium wushanense T. S. Ying]. Yao Xue Xue Bao. 1988;23(1):34–7. pmid:3400473
  2. 2. Huang JH, Cai WJ, Zhang XM, Shen ZY. Icariin promotes self-renewal of neural stem cells: an involvement of extracellular regulated kinase signaling pathway. Chinese journal of integrative medicine. 2014;20(2):107–15. pmid:24619236
  3. 3. Gao YN, Wang DY, Pan ZF, Mei YQ, Wang ZQ, Zhu DY, et al. [Phenotype-based primary screening for drugs promoting neuronal subtype differentiation in embryonic stem cells with light microscope]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012;41(4):373–80. pmid:22927071
  4. 4. Zhang H, Liu B, Wu J, Xu C, Tao J, Duan X, et al. Icariin inhibits corticosterone-induced apoptosis in hypothalamic neurons via the PI3-K/Akt signaling pathway. Molecular medicine reports. 2012;6(5):967–72. pmid:22923091
  5. 5. Yang CR, Chen JD. Preparation and biological evaluation of chitosan-collagen-icariin composite scaffolds for neuronal regeneration. Neurol Sci. 2013;34(6):941–7. pmid:22833221
  6. 6. Chen Y, Huang JH, Ning Y, Shen ZY. [Icariin and its pharmaceutical efficacy: research progress of molecular mechanism]. Zhong Xi Yi Jie He Xue Bao. 2011;9(11):1179–84. pmid:22088582
  7. 7. Liu B, Zhang H, Xu C, Yang G, Tao J, Huang J, et al. Neuroprotective effects of icariin on corticosterone-induced apoptosis in primary cultured rat hippocampal neurons. Brain research. 2011;1375:59–67. pmid:21182828
  8. 8. Urano T, Tohda C. Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid beta-induced neurite atrophy. Phytotherapy research: PTR. 2010;24(11):1658–63. pmid:21031624
  9. 9. Zeng KW, Ko H, Yang HO, Wang XM. Icariin attenuates beta-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. Neuropharmacology. 2010;59(6):542–50. pmid:20708632
  10. 10. Li F, Gong QH, Wu Q, Lu YF, Shi JS. Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in rats. Pharmacology, biochemistry, and behavior. 2010;96(3):301–5. pmid:20566405
  11. 11. Zhang L, Huang S, Chen Y, Wang Z, Li E, Xu Y. Icariin inhibits hydrogen peroxide-mediated cytotoxicity by up-regulating sirtuin type 1-dependent catalase and peroxiredoxin. Basic Clin Pharmacol Toxicol. 2010;107(5):899–905. pmid:20533910
  12. 12. Zhu HR, Wang ZY, Zhu XL, Wu XX, Li EG, Xu Y. Icariin protects against brain injury by enhancing SIRT1-dependent PGC-1alpha expression in experimental stroke. Neuropharmacology. 2010;59(1–2):70–6.
  13. 13. Zeng KW, Fu H, Liu GX, Wang XM. Icariin attenuates lipopolysaccharide-induced microglial activation and resultant death of neurons by inhibiting TAK1/IKK/NF-kappaB and JNK/p38 MAPK pathways. Int Immunopharmacol. 2010;10(6):668–78. pmid:20347053
  14. 14. Shindel AW, Xin ZC, Lin G, Fandel TM, Huang YC, Banie L, et al. Erectogenic and neurotrophic effects of icariin, a purified extract of horny goat weed (Epimedium spp.) in vitro and in vivo. The journal of sexual medicine. 2010;7(4 Pt 1):1518–28. pmid:20141584
  15. 15. Li L, Tsai HJ, Wang XM. Icariin inhibits the increased inward calcium currents induced by amyloid-beta(25–35) peptide in CA1 pyramidal neurons of neonatal rat hippocampal slice. Am J Chin Med. 2010;38(1):113–25. pmid:20128049
  16. 16. Sha D, Li L, Ye L, Liu R, Xu Y. Icariin inhibits neurotoxicity of beta-amyloid by upregulating cocaine-regulated and amphetamine-regulated transcripts. Neuroreport. 2009;20(17):1564–7. pmid:19858766
  17. 17. Wang L, Zhang L, Chen ZB, Wu JY, Zhang X, Xu Y. Icariin enhances neuronal survival after oxygen and glucose deprivation by increasing SIRT1. Eur J Pharmacol. 2009;609(1–3):40–4. pmid:19374878
  18. 18. Zheng M, Qu L, Lou Y. Effects of icariin combined with Panax notoginseng saponins on ischemia reperfusion-induced cognitive impairments related with oxidative stress and CA1 of hippocampal neurons in rat. Phytother Res. 2008;22(5):597–604. pmid:18398927
  19. 19. Li L, Zhou QX, Shi JS. Protective effects of icariin on neurons injured by cerebral ischemia/reperfusion. Chin Med J (Engl). 2005;118(19):1637–43. pmid:16232349
  20. 20. Kuroda M, Mimaki Y, Sashida Y, Umegaki E, Yamazaki M, Chiba K, et al. Flavonol glycosides from Epimedium sagittatum and their neurite outgrowth activity on PC12h cells. Planta Med. 2000;66(6):575–7. pmid:10985091
  21. 21. Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafa R, et al. Strand-specific miR-28–5p and miR-28–3p have distinct effects in colorectal cancer cells. Gastroenterology. 2012;142(4):886–96 e9. pmid:22240480
  22. 22. Beier UH, Akimova T, Liu Y, Wang L, Hancock WW. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells. Curr Opin Immunol. 2011;23(5):670–8. pmid:21798734
  23. 23. Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J. 2011;30(2):249–62. pmid:21131905
  24. 24. Oh SY, Park JU, Zheng T, Kim YK, Wu F, Cho SH, et al. Cbl-b regulates airway mucosal tolerance to aeroallergen. Clin Exp Allergy. 2011;41(3):434–42. pmid:20738317
  25. 25. Atanassov BS, Evrard YA, Multani AS, Zhang Z, Tora L, Devys D, et al. Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell. 2009;35(3):352–64. pmid:19683498
  26. 26. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell. 2008;32(1):11–20. pmid:18851829
  27. 27. Albert Y, Whitehead J, Eldredge L, Carter J, Gao X, Tourtellotte WG. Transcriptional regulation of myotube fate specification and intrafusal muscle fiber morphogenesis. J Cell Biol. 2005;169(2):257–68. pmid:15837802
  28. 28. Guo J, Li F, Wu Q, Gong Q, Lu Y, Shi J. Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats. Phytomedicine. 2010;17(12):950–5. pmid:20382007
  29. 29. Nie J, Luo Y, Huang XN, Gong QH, Wu Q, Shi JS. Icariin inhibits beta-amyloid peptide segment 25–35 induced expression of beta-secretase in rat hippocampus. Eur J Pharmacol. 2010;626(2–3):213–8. pmid:19854169
  30. 30. Luo Y, Nie J, Gong QH, Lu YF, Wu Q, Shi JS. Protective effects of icariin against learning and memory deficits induced by aluminium in rats. Clinical and experimental pharmacology & physiology. 2007;34(8):792–5.
  31. 31. Zhou H, Yuan Y, Liu Y, Deng W, Zong J, Bian ZY, et al. Icariin attenuates angiotensin II-induced hypertrophy and apoptosis in H9c2 cardiomyocytes by inhibiting reactive oxygen species-dependent JNK and p38 pathways. Experimental and therapeutic medicine. 2014;7(5):1116–22. pmid:24940396
  32. 32. Song L, Zhao J, Zhang X, Li H, Zhou Y. Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor-mediated ERK and JNK signal activation. Eur J Pharmacol. 2013;714(1–3):15–22.
  33. 33. Li WW, Gao XM, Wang XM, Guo H, Zhang BL. Icariin inhibits hydrogen peroxide-induced toxicity through inhibition of phosphorylation of JNK/p38 MAPK and p53 activity. Mutat Res. 2011;708(1–2):1–10. pmid:21315088
  34. 34. Li S, Dong P, Wang J, Zhang J, Gu J, Wu X, et al. Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Lett. 2010;298(2):222–30. pmid:20674153
  35. 35. Marshall BA, Permutt MA, Paciorkowski AR, Hoekel J, Karzon R, Wasson J, et al. Phenotypic characteristics of early Wolfram syndrome. Orphanet journal of rare diseases. 2013;8(1):64.
  36. 36. Chen P, Burdette AJ, Porter JC, Ricketts JC, Fox SA, Nery FC, et al. The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Hum Mol Genet. 2010;19(18):3502–15. pmid:20584926
  37. 37. Nassif M, Matus S, Castillo K, Hetz C. Amyotrophic lateral sclerosis pathogenesis: a journey through the secretory pathway. Antioxid Redox Signal. 2010;13(12):1955–89. pmid:20560784
  38. 38. Paschen W, Mengesdorf T. Endoplasmic reticulum stress response and neurodegeneration. Cell calcium. 2005;38(3–4):409–15. pmid:16219349
  39. 39. Paschen W. Endoplasmic reticulum: a primary target in various acute disorders and degenerative diseases of the brain. Cell Calcium. 2003;34(4–5):365–83. pmid:14572806
  40. 40. Mengesdorf T, Jensen PH, Mies G, Aufenberg C, Paschen W. Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease? Proc Natl Acad Sci U S A. 2002;99(23):15042–7. pmid:12415119
  41. 41. Paschen W. Dependence of vital cell function on endoplasmic reticulum calcium levels: implications for the mechanisms underlying neuronal cell injury in different pathological states. Cell Calcium. 2001;29(1):1–11. pmid:11133351
  42. 42. Paschen W, Doutheil J. Disturbances of the functioning of endoplasmic reticulum: a key mechanism underlying neuronal cell injury? J Cereb Blood Flow Metab. 1999;19(1):1–18. pmid:9886350
  43. 43. Carvalho P, Goder V, Rapoport TA. Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins. Cell. 2006;126(2):361–73. pmid:16873066
  44. 44. Denic V, Quan EM, Weissman JS. A luminal surveillance complex that selects misfolded glycoproteins for ER-associated degradation. Cell. 2006;126(2):349–59. pmid:16873065
  45. 45. Amano T, Yamasaki S, Yagishita N, Tsuchimochi K, Shin H, Kawahara K, et al. Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. Genes Dev. 2003;17(19):2436–49. pmid:12975321
  46. 46. Gao B, Calhoun K, Fang D. The proinflammatory cytokines IL-1beta and TNF-alpha induce the expression of Synoviolin, an E3 ubiquitin ligase, in mouse synovial fibroblasts via the Erk1/2-ETS1 pathway. Arthritis research & therapy. 2006;8(6):R172.
  47. 47. Nomura Y. Neuronal apoptosis and protection: effects of nitric oxide and endoplasmic reticulum-related proteins. Biol Pharm Bull. 2004;27(7):961–3. pmid:15256722
  48. 48. Gao B, Lee SM, Chen A, Zhang J, Zhang DD, Kannan K, et al. Synoviolin promotes IRE1 ubiquitination and degradation in synovial fibroblasts from mice with collagen-induced arthritis. EMBO Rep. 2008;9(5):480–5. pmid:18369366
  49. 49. Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T, et al. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. The EMBO journal. 2007;26(1):113–22. pmid:17170702
  50. 50. Gao B, Lee SM, Fang D. The tyrosine kinase c-Abl protects c-Jun from ubiquitination-mediated degradation in T cells. J Biol Chem. 2006;281(40):29711–8. pmid:16901904
  51. 51. Chen A, Gao B, Zhang J, McEwen T, Ye SQ, Zhang D, et al. The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-cell death by catalyzing EGR2 ubiquitination. Mol Cell Biol. 2009;29(19):5348–56. pmid:19651900
  52. 52. Lee SM, Gao B, Fang D. FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood. 2008;111(7):3599–606. pmid:18223166
  53. 53. Kong S, Kim SJ, Sandal B, Lee SM, Gao B, Zhang DD, et al. The type III histone deacetylase Sirt1 protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclaf1 promoter to inhibit T cell activation. The Journal of biological chemistry. 2011;286(19):16967–75. pmid:21454709
  54. 54. Zhang J, Lee SM, Shannon S, Gao B, Chen W, Chen A, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. The Journal of clinical investigation. 2009;119(10):3048–58. pmid:19729833
  55. 55. Kaneko M, Koike H, Saito R, Kitamura Y, Okuma Y, Nomura Y. Loss of HRD1-mediated protein degradation causes amyloid precursor protein accumulation and amyloid-beta generation. J Neurosci. 2010;30(11):3924–32. pmid:20237263
  56. 56. Lee CS, Lee C, Hu T, Nguyen JM, Zhang J, Martin MV, et al. Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proc Natl Acad Sci U S A. 2011;108(20):8408–13. pmid:21536885
  57. 57. Saito R, Kaneko M, Kitamura Y, Takata K, Kawada K, Okuma Y, et al. Effects of oxidative stress on the solubility of HRD1, a ubiquitin ligase implicated in Alzheimer's disease. PLoS One. 2014;9(5):e94576. pmid:24788773
  58. 58. Kawada K, Iekumo T, Saito R, Kaneko M, Mimori S, Nomura Y, et al. Aberrant neuronal differentiation and inhibition of dendrite outgrowth resulting from endoplasmic reticulum stress. Journal of neuroscience research. 2014.
  59. 59. Zemoura K, Schenkel M, Acuna MA, Yevenes GE, Zeilhofer HU, Benke D. Endoplasmic reticulum-associated degradation controls cell surface expression of gamma-aminobutyric acid, type B receptors. J Biol Chem. 2013;288(48):34897–905. pmid:24114844
  60. 60. Roussel BD, Newton TM, Malzer E, Simecek N, Haq I, Thomas SE, et al. Sterol metabolism regulates neuroserpin polymer degradation in the absence of the unfolded protein response in the dementia FENIB. Hum Mol Genet. 2013;22(22):4616–26. pmid:23814041
  61. 61. Kaneko M. [Molecular pharmacological studies on the protection mechanism against endoplasmic reticulum stress-induced neurodegenerative disease]. Yakugaku Zasshi. 2012;132(12):1437–42. pmid:23208051
  62. 62. Shen YX, Sun AM, Fang S, Feng LJ, Li Q, Hou HL, et al. Hrd1 facilitates tau degradation and promotes neuron survival. Curr Mol Med. 2012;12(2):138–52. pmid:22280354
  63. 63. Kawada K, Kaneko M, Nomura Y, Mimori S, Hamana H, Ogita K, et al. Expression of the ubiquitin ligase HRD1 in neural stem/progenitor cells of the adult mouse brain. Journal of pharmacological sciences. 2011;117(3):208–12. pmid:22027098
  64. 64. Ying Z, Wang H, Fan H, Wang G. The endoplasmic reticulum (ER)-associated degradation system regulates aggregation and degradation of mutant neuroserpin. J Biol Chem. 2011;286(23):20835–44. pmid:21507957
  65. 65. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, et al. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res. 2011;89(7):1031–42. pmid:21488093
  66. 66. Saito R, Kaneko M, Okuma Y, Nomura Y. Correlation between decrease in protein levels of ubiquitin ligase HRD1 and amyloid-beta production. Journal of pharmacological sciences. 2010;113(3):285–8. pmid:20606367
  67. 67. Mei J, Niu C. Alterations of Hrd1 expression in various encephalic regional neurons in 6-OHDA model of Parkinson's disease. Neurosci Lett. 2010;474(2):63–8. pmid:20227462
  68. 68. Omura T, Kaneko M, Tabei N, Okuma Y, Nomura Y. Immunohistochemical localization of a ubiquitin ligase HRD1 in murine brain. Journal of neuroscience research. 2008;86(7):1577–87. pmid:18241051
  69. 69. Omura T, Kaneko M, Okuma Y, Orba Y, Nagashima K, Takahashi R, et al. A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin. J Neurochem. 2006;99(6):1456–69. pmid:17059562
  70. 70. Tsuchiya Y, Morita T, Kim M, Iemura S, Natsume T, Yamamoto M, et al. Dual regulation of the transcriptional activity of Nrf1 by beta-TrCP- and Hrd1-dependent degradation mechanisms. Mol Cell Biol. 2011;31(22):4500–12. pmid:21911472
  71. 71. Steffen J, Seeger M, Koch A, Kruger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Molecular cell. 2010;40(1):147–58. pmid:20932482
  72. 72. Wu T, Zhao F, Gao B, Tan C, Yagishita N, Nakajima T, et al. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes & development. 2014;28(7):708–22.
  73. 73. Tsuchimochi K, Yagishita N, Yamasaki S, Amano T, Kato Y, Kawahara K, et al. Identification of a crucial site for synoviolin expression. Mol Cell Biol. 2005;25(16):7344–56. pmid:16055742
  74. 74. Izumi T, Fujii R, Izumi T, Nakazawa M, Yagishita N, Tsuchimochi K, et al. Activation of synoviolin promoter in rheumatoid synovial cells by a novel transcription complex of interleukin enhancer binding factor 3 and GA binding protein alpha. Arthritis Rheum. 2009;60(1):63–72. pmid:19116932
  75. 75. Bordallo J, Plemper RK, Finger A, Wolf DH. Der3p/Hrd1p is required for endoplasmic reticulum-associated degradation of misfolded lumenal and integral membrane proteins. Molecular biology of the cell. 1998;9(1):209–22. pmid:9437001